文献速递重症综合管理与镇静镇痛儿科与产科急症

急诊科急性躁动治疗:肌内注射咪达唑仑、奥氮平、齐拉西酮或氟哌啶醇的比较

Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.
PubMed 文献 · Ann Emerg Med · 2018-06-07
一句话结论急诊躁动患者肌内注射咪达唑仑15分钟充分镇静比例高于氟哌啶醇、齐拉西酮,可能高于奥氮平;奥氮平优于氟哌啶醇;不良事件无差异。

本研究为前瞻性观察研究,连续纳入急诊科接受肌内注射药物治疗躁动的737例患者(中位年龄40岁,72%男性)。按预定的3周区块顺序给予氟哌啶醇5 mg、齐拉西酮20 mg、奥氮平10 mg、咪达唑仑5 mg、氟哌啶醇10 mg。主要终点为15分钟时采用精神状态改变量表评估的充分镇静比例。结果显示咪达唑仑充分镇静比例高于齐拉西酮(差异18%,95%CI 6%~29%)、氟哌啶醇5 mg(差异30%,95%CI 19%~41%)、氟哌啶醇10 mg(差异28%,95%CI 17%~39%)及奥氮平(差异9%,95%CI -1%~20%);奥氮平高于氟哌啶醇5 mg(差异20%,95%CI 10%~31%)和10 mg(差异18%,95%CI 7%~29%),与齐拉西酮差异未达统计学显著(差异8%,95%CI -3%~19%)。不良事件少见且各组相似。

要点

  • 急诊躁动患者肌内注射咪达唑仑5 mg在15分钟时充分镇静(AMSS<1)比例高于氟哌啶醇5 mg(差异30%,95%CI 19%~41%)和10 mg(差异28%,95%CI 17%~39%)。
  • 咪达唑仑5 mg充分镇静比例高于齐拉西酮20 mg(差异18%,95%CI 6%~29%),与奥氮平10 mg差异未达统计学显著(差异9%,95%CI -1%~20%)。
  • 奥氮平10 mg充分镇静比例高于氟哌啶醇5 mg(差异20%,95%CI 10%~31%)和10 mg(差异18%,95%CI 7%~29%),与齐拉西酮20 mg差异未达统计学显著(差异8%,95%CI -3%~19%)。
  • 不良事件少见且各组相似:心脏骤停0例、锥体外系不良反应2例(0.3%)、低血压5例(0.5%)、低氧血症10例(1%)、插管4例(0.5%)。

适用人群与场景

  • 急诊科连续纳入的接受肌内注射药物治疗躁动的患者(中位年龄40岁,72%男性)。

诊断标准与关键阈值

  • 采用精神状态改变量表(Altered Mental Status Scale)评估,充分镇静定义为量表评分<1。

处置流程与药物剂量

  • 按预先设定的3周区块顺序给予肌内注射药物:氟哌啶醇5 mg、齐拉西酮20 mg、奥氮平10 mg、咪达唑仑5 mg、氟哌啶醇10 mg。

研究设计与关键结果

  • 前瞻性观察研究,纳入737例急诊躁动患者,按3周区块顺序接受肌内注射氟哌啶醇5 mg、齐拉西酮20 mg、奥氮平10 mg、咪达唑仑5 mg或氟哌啶醇10 mg。
  • 15分钟时咪达唑仑组充分镇静比例高于齐拉西酮组(差异18%,95%CI 6%~29%)、氟哌啶醇5 mg组(差异30%,95%CI 19%~41%)、氟哌啶醇10 mg组(差异28%,95%CI 17%~39%),与奥氮平组差异未达统计学显著(差异9%,95%CI -1%~20%)。
  • 奥氮平组充分镇静比例高于氟哌啶醇5 mg组(差异20%,95%CI 10%~31%)和氟哌啶醇10 mg组(差异18%,95%CI 7%~29%),与齐拉西酮组差异未达统计学显著(差异8%,95%CI -3%~19%)。
  • 不良事件各组相似:心脏骤停0例、锥体外系不良反应2例(0.3%)、低血压5例(0.5%)、低氧血症10例(1%)、插管4例(0.5%)。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊科躁动需肌内注射药物治疗的患者,作者结论认为咪达唑仑5 mg在15分钟时镇静效果优于氟哌啶醇、齐拉西酮,可能优于奥氮平;奥氮平10 mg镇静效果优于氟哌啶醇。
  • 不良事件少见且各组相似,但原文为观察性研究,结论需结合临床情况判断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Agitation in the emergency department (ED) can pose a threat to patient and provider safety; therefore, treatment is indicated. The purpose of this study is to compare haloperidol, olanzapine, midazolam, and ziprasidone to treat agitation.

METHODS: This was a prospective observational study of consecutive patients receiving intramuscular medication to treat agitation in the ED. Medications were administered according to an a priori protocol in which the initial medication given was predetermined in the following 3-week blocks: haloperidol 5 mg, ziprasidone 20 mg, olanzapine 10 mg, midazolam 5 mg, and haloperidol 10 mg. The primary outcome was the proportion of patients adequately sedated at 15 minutes, assessed with the Altered Mental Status Scale.

RESULTS: Seven hundred thirty-seven patients were enrolled (median age 40 years; 72% men). At 15 minutes, midazolam resulted in a greater proportion of patients adequately sedated (Altered Mental Status Scale <1) compared with ziprasidone (difference 18%; 95% confidence interval [CI] 6% to 29%), haloperidol 5 mg (difference 30%; 95% CI 19% to 41%), haloperidol 10 mg (difference 28%; 95% CI 17% to 39%), and olanzapine (difference 9%; 95% CI -1% to 20%). Olanzapine resulted in a greater proportion of patients adequately sedated at 15 minutes compared with haloperidol 5 mg (difference 20%; 95% CI 10% to 31%), haloperidol 10 mg (difference 18%; 95% CI 7% to 29%), and ziprasidone (difference 8%; 95% CI -3% to 19%). Adverse events were uncommon: cardiac arrest (0), extrapyramidal adverse effects (2; 0.3%), hypotension (5; 0.5%), hypoxemia (10; 1%), and intubation (4; 0.5%), and occurred at similar rates in each group.

CONCLUSION: Intramuscular midazolam achieved more effective sedation in agitated ED patients at 15 minutes than haloperidol, ziprasidone, and perhaps olanzapine. Olanzapine provided more effective sedation than haloperidol. No differences in adverse events were identified.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Klein LR, Driver BE, Miner JR, et al. Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department. Ann Emerg Med. 2018. PMID: 29885904. doi:10.1016/j.annemergmed.2018.04.027

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。